A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice.

Trial Profile

A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 May 2014

At a glance

  • Drugs Ezetimibe; Fenofibrate; HMG-CoA reductase inhibitors
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 May 2014 Last checked against ClinicalTrials.gov: US National Institutes of Health.
    • 30 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top